Cancer Molecular Imaging, Nanotechnology and Theranostics

癌症分子成像、纳米技术和治疗学研究计划(CMINT) 摘要 癌症分子成像、纳米技术和基因组学研究计划(CMINT)吹嘘 具有互补专业知识的杰出领导者，医学博士Johannes Czernin(主任)，医学博士Caius Radu(共同 董事)和杰弗里·津克博士(联席主任)。该计划的主要目标是推动翻译 以改善癌症患者预后为目标的成像、纳米颗粒设计和传递以及治疗 通过将发现转移到临床前和临床应用。CMINT计划科学具有高度的互动性和 它的45名教职员工来自加州大学洛杉矶分校的四所学校和合作机构加州理工大学， 代表16个基础和临床科室。成员在生物学方面具有不同和互补的专业知识， 核医学、物理学、纳米技术、泌尿学、放射学、放射肿瘤学、药物开发、 工程学、图像重建、化学、放射化学和疾病动物模型。CMINT 该计划将以前的癌症分子成像(CMI)研究计划与进化和有机 先前的癌症纳米技术(CN)研究计划的发展，结合对 重粒子治疗和成像。截至2019年3月1日，该计划拥有10033,965美元的直接成本资金， 其中590万美元(59%)来自NCI，895万美元(%)来自同行评审的总直接成本。计划 这些发现导致在前一个项目期间发表了1109份出版物，其中23%是方案内出版物 协作和29%是方案间协作。此外，49%的出版物代表 与外部机构的合作，35%是在影响力较大的(如果是≥10或领域领先的)期刊上。这个 该计划贡献了14项专利，5项批准的IND和9家初创公司。在之前的项目期内， 共有93项临床试验由计划成员发起，共有11,807人参与。CMINT有四个 具体目标是推进主要计划的目标和目标，包括：(1)开发仪器， 分析工具和新的分子成像方法；(2)成像免疫反应和对 免疫疗法；(3)基于纳米技术的工程成像和治疗输送系统；以及(4) 将诊断和治疗方法转化为临床。在这些目标中嵌入了研究，以 揭示多肽受体放射性核素(PRRT)和放射性配基(RLT)的靶向耐药机制 治疗，并评估具有高翻译潜力的新型治疗对。其他研究包括 开发和转化新的分子成像技术和方法学以提高诊断水平 和癌症的治疗，并使用光学、放射性[PET/SPECT]光谱、MRI成像和非 成像方法，如质谱仪，以扩大分子成像和治疗的范围。CMINT 计划成员继续强调在PET成像领域的机遇和领先地位，同时在 其他成像方式，包括mpMRI，以及在纳米颗粒试剂中添加强大的概念 对其核心工作的交付和治疗。

CANCER MOLECULAR IMAGING, NANOTECHNOLOGY, AND THERANOSTICS RESEARCH PROGRAM (CMINT) ABSTRACT The Cancer Molecular Imaging, Nanotechnology, and Theranostics Research Program (CMINT) boasts accomplished leaders with complementary expertise, Johannes Czernin, MD (Director), Caius Radu, MD (Co- Director), and Jeffrey Zink, PhD (Co-Director). The primary Program objective is to advance translational imaging, nanoparticle design and delivery, and theranostics with the goal of improving cancer patient outcomes by moving discoveries to preclinical and clinical applications. CMINT Program science is highly interactive and transdisciplinary, with its 45 faculty members drawn from four UCLA schools and partner institution, Caltech, representing 16 basic and clinical departments. Members have diverse and complementary expertise in biology, nuclear medicine, physics, nanotechnology, urology, radiology, radiation oncology, drug development, engineering, image reconstruction, chemistry, radiochemistry, and animal models of disease. The CMINT Program merges the former Cancer Molecular Imaging (CMI) Research Program with the evolution and organic development of the prior Cancer Nanotechnology (CN) Research Program, combined with a new emphasis on heavy particle therapy and imaging. As of March 1, 2019, the Program has $10,033,965 in direct cost funding, including $5.9M (59%) from the NCI, and $8.95M (89%) in total direct cost peer-reviewed funding. Program discoveries resulted in 1,109 publications over the prior project period, of which 23% are intra-programmatic collaborations and 29% are inter-programmatic collaborations. In addition, 49% of publications represent collaborations with external institutions and 35% are in high-impact (IF ≥10, or field leading) journals. The Program contributed 14 patents, five approved INDs, and nine start-up companies. In the prior project period, there were 93 clinical trials initiated by Program members with 11,807 individuals accrued. CMINT has four specific aims to advance the primary Program objective and goal, including: (1) Developing instrumentation, analytical tools, and novel molecular imaging approaches; (2) Imaging immune responses and responses to immunotherapy; (3) Engineering nanotechnology-based imaging and therapeutic delivery systems; and (4) Translating diagnostic and theranostic approaches into the clinic. Embedded within these aims are studies to uncover and then target resistance mechanisms in peptide receptor radionuclide (PRRT) and radioligand (RLT) therapies, and to evaluate novel theranostic pairs with high translational potential. Additional studies include developing and translating new molecular imaging technologies and methodologies to improve the diagnosis and treatment of cancer, and using a spectrum of optical, radioactive [PET/SPECT], and MRI imaging and non- imaging approaches, such as mass-spectrometry, to extend the reach of molecular imaging and therapy. CMINT Program members continue to emphasize opportunities and lead in PET imaging while building strength in additional imaging modalities that include mpMRI, along with adding powerful concepts in nanoparticle agent delivery and theranostics to its core efforts.